Urgent.News

What's breaking now, across hundreds of outlets.

Finance & Markets

Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here’s Why the Streak Looks Safe.

Gilead's consistent cash flows from HIV therapies help sustain its dividend.

Gilead Sciences has maintained an impressive streak of raising its dividend for 11 consecutive years, increasing it by 3.8% this year. With a dividend yield of 1.94%, the company's payouts are sitting at just below 30% of its free cash flow, leaving ample room for future growth. The main driver behind Gilead's stable dividends is its dominant position in HIV therapies, providing reliable cash flow for years to come.

Furthermore, the company has been expanding into new areas like oncology, liver, and inflammation therapies. Recent highlights include the third-quarter success of Biktarvy, which generated $4.1 billion in revenue, up 10% year-over-year, and the exceptional performance of Descovy and Yeztugo, both of which have shown remarkable year-over-year growth.

While HIV therapies remain Gilead's primary revenue source, the company has been actively diversifying its portfolio with blockbuster drugs such as Trodelvy and promising oncology programs in development. With a solid cash position and a diverse range of revenue streams, Gilead's dividend appears to be a safe and promising investment.

Rewritten by urgent.news; may contain errors — check the original.

Sources: fool.com · nasdaq.com

Also reported by 1 other outlet

Every outlet that reported this, and when →

Read the original at fool.com →

Report a problem with this story

More in Finance & Markets

More from Sunday 22 November →